Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism
AssigneeStrongbridge Dublin Limited
InventorFred Cohen
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for treating congenital adrenal hyperplasia or primary aldosteronism in a subject in need thereof, comprising administering a therapeutically effective amount of 2S,4R ketoconazole enantiomer substantially free of the 2R,4S ketoconazole enantiomer to the subject. Also disclosed are compositions comprising a therapeutically effective amount of 2S,4R ketoconazole enantiomer substantially free of the 2R,4S ketoconazole enantiomer for use in treating a disease or condition associated with congenital adrenal hyperplasia or primary aldosteronism.
Claims16
A method for treating congenital adrenal hyperplasia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of 2S,4R ketoconazole enantiomer, wherein the ketoconazole content of the therapeutically effective amount comprises less than 20% 2R,4S enantiomer and more than 80% 2S,4R enantiomer, and wherein 11-deoxycortisol (11-DOC) secretion is not substantially increased after administration of the 2S, 4R ketoconazole enantiomer.
A method for treating primary aldosteronism in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of 2S,4R ketoconazole enantiomer, wherein the ketoconazole content of the therapeutically effective amount comprises less than 20% of 2R,4S enantiomer and more than 80% of 2S,4R enantiomer, and wherein 11-DOC secretion is not substantially increased after administration of the 2S, 4R ketoconazole enantiomer.
Dependencies are inferred from the claim text.